World's Best Scientists 2026 revealed!
Michael J. O'Connell

Michael J. O'Connell

D-Index & Metrics

Medicine

D-Index
104
Citations
45754
World Ranking
6991
National Ranking
3677

Michael J. O'Connell publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael J. O'Connell sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 364 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael J. O'Connell D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. O'Connell sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael J. O'Connell is affiliated with the Mayo Clinic in the United States and has contributed extensively to research in medicine, biochemistry, genetics, and molecular biology. Their work spans various subfields, prominently molecular biology and oncology, with additional focus on ecology, pathology and forensic medicine, and surgery.

Their research primarily centers on colorectal cancer, covering treatments, genetic factors, screening, detection, and surgical approaches. Other significant topics include gene expression and cancer classification, bioinformatics and genomic networks, and colorectal and anal carcinomas.

Recent published papers include the following:

  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials (2020, Journal of Clinical Oncology)
  • Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database (2020, JNCI Journal of the National Cancer Institute)
  • Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database (2021, JNCI Journal of the National Cancer Institute)
  • Lens Epithelial Explants Treated with Vitreous Humor Undergo Alterations in Chromatin Landscape with Concurrent Activation of Genes Associated with Fiber Cell Differentiation and Innate Immune Response (2023, Cells)
  • Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology (2020, Diseases of the Colon & Rectum)

Frequent co-authors collaborating with Michael J. O'Connell include:

  • Richard M. Goldberg
  • Greg Yothers
  • Carmen J. Allegra
  • Norman Wolmark
  • Aimery de Gramont

Their work is published across various venues, with notable contributions in:

  • UNC Libraries
  • bioRxiv (Cold Spring Harbor Laboratory)
  • JNCI Journal of the National Cancer Institute
  • Bioinformatics Advances
  • Journal of Clinical Oncology

Michael J. O'Connell's academic production features a strong interdisciplinary approach, integrating molecular biology and oncology to investigate colorectal cancer's clinical and molecular characteristics. Their research provides data-driven analysis in chemotherapy effects, genetic instability, and cancer pathology reporting, reflecting broad expertise in medicine and genomic sciences.

Best Publications

  • Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

    C. G. Moertel;S. Frytak;R. G. Hahn;M. J. O'Connell

  • Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

    Michael J. O'Connell;James A. Martenson;Harry S. Wieand;James E. Krook

  • Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    J. Philip Kuebler;H. Samuel Wieand;Michael J. O'Connell;Roy E. Smith

  • Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

    M A Poon;M J O'Connell;C G Moertel;H S Wieand

  • Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

    Larry K. Kvols;Charles G. Moertel;Michael J. O'Connell;Allan J. Schutt

  • Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

    Charles G. Moertel;Larry K. Kvols;Michael J. O'Connell;Joseph Rubin

  • Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

    Mark S. Roh;Linda H. Colangelo;Michael J. O'Connell;Greg Yothers

  • High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.

    Charles G. Moertel;Thomas R. Fleming;Edward T. Creagan;Joseph Rubin

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

    M J O'Connell;J A Mailliard;M J Kahn;J S Macdonald

  • Impact of Number of Nodes Retrieved on Outcome in Patients With Rectal Cancer

    Joel E. Tepper;Michael J. O’Connell;Donna Niedzwiecki;Donna Hollis

  • Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1.

    Stephen N. Thibodeau;Amy J. French;Julie M. Cunningham;David Tester

  • Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.

    Edward T. Creagan;Charles G. Moertel;Judith R. O'Fallon;Allan J. Schutt

  • Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

    Greg Yothers;Michael J. O'Connell;Carmen J. Allegra;J. Philip Kuebler

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

    Carmen J. Allegra;Greg Yothers;Michael J. O'Connell;Saima Sharif

  • Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.

    P Piedbois;M Buyse;N Kemeny

  • Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer A Pooled Analysis

    Leonard L. Gunderson;Daniel Jay Sargent;Joel E. Tepper;Norman Wolmark

  • Carcinoma of the anal canal, a clinical and pathologic study of 188 cases

    Bruce M. Boman;Charles G. Moertel;Michael J. O'Connell;Mark Scott

  • Intra-arterial Floxuridine vs Systemic Fluorouracil for Hepatic Metastases From Colorectal Cancer: A Randomized Trial

    J. Kirk Martin;Michael J. O'Connell;Harry S. Wieand;Robert J. Fitzgibbons

Frequent Co-Authors

Joseph Rubin
Joseph Rubin Mayo Clinic
Norman Wolmark
Norman Wolmark University of Pittsburgh
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Larry K. Kvols
Larry K. Kvols University of South Florida
Carmen J. Allegra
Carmen J. Allegra University of Florida
Martin M. Oken
Martin M. Oken University of Minnesota
Daniel G. Haller
Daniel G. Haller University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the field of medicine evolves, so do the diverse career options and educational pathways available to students. For those looking to expand their expertise without attending traditional on-campus programs, there are several accredited online degrees that can support your ambitions in healthcare.

A health administration degree online is an excellent starting point for students interested in the organizational and business side of healthcare. For those seeking leadership roles, a master's in healthcare administration online offers advanced training in management, policy, and strategic planning.

Nurses aiming for top clinical roles can pursue the best dnp programs online, equipping them with the clinical and leadership skills needed for advanced nursing practice. Meanwhile, pharmacy professionals looking to accelerate their careers may benefit from a 3 year online pharmd program, which offers a flexible and efficient route to earn a Doctor of Pharmacy degree.

Exploring these online degree options can open doors to dynamic roles in the ever-expanding healthcare sector, providing flexibility and accessibility for aspiring professionals worldwide.

Best Scientists Citing Michael J. O'Connell

Trending Scientists